Nanobiotix starts a new research program, in Immuno Oncology, with its lead product NBTXR3
PARIS and CAMBRIDGE, United Kingdom, Jan. 5, 2016 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in …